Access cutting-edge partial-onset epilepsy treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access partial-onset epilepsy specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related partial-onset epilepsy treatment provided free
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno
Sponsor: SK Life Science, Inc.
Check if you qualify for this partial-onset epilepsy clinical trial in Washington Dc, DC
If you're searching for partial-onset epilepsy treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced partial-onset epilepsy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.